CLN-049
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Filters
Save & Share
Clear Filters
Location
Explore options near your center - or near your patient's home.
MDS Centers of Excellence
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Near Add Your Location
Sort by
UCLA Medical Center of Hematology/Oncology
Los Angeles, CA
- Accepting patients
Center of Excellence
- Accepting patients
Center of Excellence
- Accepting patients
Center of Excellence
Massachusetts General Hospital
Boston, MA
- Accepting patients
Center of Excellence
- Accepting patients
Cincinnati Children's Hospital Medical Center
Cincinnati, OH
- Accepting patients
Center of Excellence
- Accepting patients
509 hidden based on your filters. Show All
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.